If you’ve walked into a pharmacy lately, you know the drill. You hand over your insurance card, wait ten minutes, and then the person behind the counter tells you a number that sounds like a monthly car payment. It’s frustrating. It’s also why the trump executive order on prescription drugs became such a massive flashpoint in American politics. People are tired of paying five times more for the same pill than someone in France or Canada.
Honestly, the whole situation is a mess of legal jargon and "Most-Favored-Nation" talk that sounds like it belongs in a trade treaty, not a doctor’s office. But here’s the thing: as of January 2026, we are actually seeing the "rubber meet the road." The theory has turned into real-world pricing on shelves.
The Most-Favored-Nation (MFN) Concept Explained Simply
Basically, the core of the trump executive order on prescription drugs is the "Most-Favored-Nation" (MFN) model. The logic is dead simple. If a drug company sells an asthma inhaler to Germany for $50, why should they be allowed to charge Medicare $250 for it? Trump’s executive orders—specifically the ones revived and expanded in 2025—aimed to cap U.S. prices at the lowest price paid by other wealthy, "comparably developed" nations.
Think of it like a price match guarantee at a big-box store. If the manufacturer gives a better deal elsewhere, we want that deal too.
What Actually Changed in 2025 and 2026?
For a long time, these orders were stuck in court. Drug companies sued, arguing that price caps would kill innovation. They said if they can't make a huge profit in the U.S., they won't have the money to find a cure for Alzheimer's or cancer.
But things shifted last year. In May 2025, a new, more aggressive executive order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients" was signed. It didn't just ask nicely; it threatened to revoke drug approvals or allow importation from overseas if companies didn't play ball.
🔗 Read more: That Time a Doctor With Measles Treating Kids Sparked a Massive Health Crisis
Since then, we’ve seen some pretty wild developments:
- TrumpRx is a real thing now. It’s a direct-to-consumer program where companies sell directly to you, bypassing the "middlemen" (like Pharmacy Benefit Managers).
- Major price drops on GLP-1s. You’ve probably heard of Ozempic and Wegovy. Under new agreements reached in late 2025, prices for these through the TrumpRx portal fell from over $1,000 a month to around $350.
- The $35 Insulin Cap. While this has been a back-and-forth battle for years, the current administration’s 2025 order conditioned grants for community health centers on them providing insulin and Epipens at massive discounts to low-income patients.
- The "Great Healthcare Plan" of 2026. Just this month, the White House proposed codifying these MFN deals into permanent law so they can't be easily overturned by the next administration or a court challenge.
The Deals You Might Actually Use
It isn't just talk anymore. Major companies like Eli Lilly, Sanofi, and Amgen have signed "voluntary" agreements to avoid more drastic regulations.
If you're looking at your own medicine cabinet, here is what the trump executive order on prescription drugs has actually done to specific list prices when purchased through the new direct-to-patient channels:
Januvia (Diabetes): Dropped from $330 to about $100.
Repatha (Cholesterol): Fell from $573 to $239.
Advair Diskus (Asthma): Down from $265 to roughly $89.
Plavix (Blood Thinner): Sanofi agreed to a price of just $16 for direct purchasers.
It’s a weird shift. Instead of your insurance company negotiating a "secret" rebate that you never see, the goal here is to just lower the price at the point of sale.
💡 You might also like: Dr. Sharon Vila Wright: What You Should Know About the Houston OB-GYN
The "Global Freeloading" Argument
You’ll hear the phrase "global freeloading" a lot in these briefings. The administration’s stance is that the U.S. funds about 75% of global pharmaceutical profits. Other countries use socialized medicine to demand low prices, and the drug companies make up the difference by hiking prices on Americans.
By tying our prices to theirs, the trump executive order on prescription drugs tries to force those other countries to pay more—or force the companies to accept less profit across the board.
Critics, however, are worried. The American Medical Association (AMA) and other groups have pointed out that while lower prices are great, "site-neutral" policies (another part of these orders) might hurt hospitals that treat sicker patients. There's also the risk that if a drug becomes "unprofitable" under MFN rules, a company might just stop selling it in the U.S. altogether.
Where Do We Go From Here?
This isn't a "set it and forget it" situation. The 2026 landscape is full of new "models" being tested by CMS (Centers for Medicare & Medicaid Services).
- The GLOBE Model: This targets drugs administered in doctor’s offices (Medicare Part B). It’s basically a test run to see if we can save $11 billion by using international benchmarks.
- The GUARD Model: This is the same idea but for drugs you get at the pharmacy counter (Part D).
- Over-the-Counter Shifts: The 2026 "Great Healthcare Plan" wants to move more prescription drugs to "over-the-counter" status. This would let you buy them without a doctor’s visit, though it also means insurance might stop covering them.
How to Save Money Right Now
If you're struggling with costs, don't wait for a law to pass in Congress. The trump executive order on prescription drugs has already opened up some specific doors you should look into today.
📖 Related: Why Meditation for Emotional Numbness is Harder (and Better) Than You Think
First, check if your medication is part of the TrumpRx direct-to-patient program. Many manufacturers are now shipping directly to consumers at the "MFN price" to stay in the government's good graces.
Second, if you use a Community Health Center, ask about the 340B pricing for insulin and Epipens. Because of the April 2025 executive order, these centers are now required to pass their deep discounts directly to you if you meet certain income requirements.
Third, look into the new $50 co-pay cap for GLP-1 medications (like those for obesity) if you are on Medicare. This is a bridge program that started as a result of these recent negotiations.
The era of just "accepting" the price on the sticker is ending, but you have to be the one to ask for these specific programs. The pharmacy isn't always going to volunteer the cheapest option if it cuts into their margins. Stay informed, check the TrumpRx listings regularly, and keep a close eye on the February 2026 deadline for the next round of Medicare price negotiations.